Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Modulation of tumor growth by inhibitory Fcγ receptor expressed by human melanoma cells
Lydie Cassard, Joël F.G. Cohen-Solal, Annie Galinha, Xavier Sastre-Garau, Claire Mathiot, Jérôme Galon, Thierry Dorval, Alain Bernheim, Wolf H. Fridman, Catherine Sautès-Fridman
Lydie Cassard, Joël F.G. Cohen-Solal, Annie Galinha, Xavier Sastre-Garau, Claire Mathiot, Jérôme Galon, Thierry Dorval, Alain Bernheim, Wolf H. Fridman, Catherine Sautès-Fridman
View: Text | PDF
Article Development

Modulation of tumor growth by inhibitory Fcγ receptor expressed by human melanoma cells

  • Text
  • PDF
Abstract

Research Article

Authors

Lydie Cassard, Joël F.G. Cohen-Solal, Annie Galinha, Xavier Sastre-Garau, Claire Mathiot, Jérôme Galon, Thierry Dorval, Alain Bernheim, Wolf H. Fridman, Catherine Sautès-Fridman

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Anti-GD2 mAb inhibits growth of FcγRIIB1-positive tumor cells in vitro a...
Anti-GD2 mAb inhibits growth of FcγRIIB1-positive tumor cells in vitro and in vivo, in an intracytoplasmic-dependent manner. (a) Expression of GD2 on cells as assessed by flow cytometry using 7A4 or a control isotype (dotted histograms). (b) Inhibition of proliferation of melanoma cells in vitro. Cells (5 × 103 cells per well) were incubated with the indicated concentrations of anti-GD2 mAb 7A4 (filled symbols) or control mouse IgG3 (open symbols). 3H-thymidine incorporation rate and percentages of inhibition were measured as described in Figure 5. Each point represents results from three independent experiments performed in triplicate (mean ± SD). (c and d) Inhibition of growth of HT144IIB1 but not of HT144IIB(Cyto–) tumors in SCID mice injected intravenously with anti-GD2 mAb. SCID mice were inoculated subcutaneously with 2 × 106 HT144IIB1 (c) and HT144IIB(Cyto–) (d) cells, followed by biweekly intravenous injections of 50 μg of mAb 7A4 (filled symbols) or PBS (open symbols). Eight mice were used per experiment in each group, and mean tumor volume values, with SD, of mice bearing tumor are shown. *P < 0.05, **P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts